1,12-cyclic-Apelin-12 counters vascular smooth muscle cell proliferation and atherosclerosis by inhibiting aerobic glycolysis
Background
Atherosclerosis is a chronic vascular disease characterized by the accumulation of plaque within arteries, leading to significant cardiovascular morbidity. A key driver of this pathology is vascular smooth muscle cell (VSMC) phenotypic switching, migration, and excessive proliferation, which contribute to plaque growth and instability. Traditional treatments often target lipid levels or inflammation, but directly addressing VSMC proliferation and its metabolic underpinnings remains a critical therapeutic gap. Previous research identified Apelin-13 as a peptide that promotes aerobic glycolysis and stimulates VSMC proliferation, suggesting that modulating this pathway could offer a novel therapeutic strategy for atherosclerosis.
Study Design
Researchers developed a novel peptide, 1,12-cyclic Apelin-12 (c-Apelin-12), by cyclizing the N- and C-termini of Apelin-12 via an amide bond. In vitro, they investigated c-Apelin-12's effects on Apelin-13-induced VSMC proliferation, mitochondrial injury, and aerobic glycolysis. The specific cell line, doses, and duration for these in vitro experiments were not detailed in the abstract. In vivo, they administered c-Apelin-12 to an unspecified animal model of atherosclerosis to assess its impact on atherosclerotic plaque formation and the expression of proliferation-associated markers and key glycolytic enzymes. The animal species, dose, route, and frequency of c-Apelin-12 treatment were not specified.
Results
The novel c-Apelin-12 peptide demonstrated significant therapeutic potential by counteracting the pro-atherogenic effects of Apelin-13. In vitro experiments revealed that c-Apelin-12 effectively attenuated Apelin-13-induced VSMC proliferation. Furthermore, it reduced mitochondrial injury and suppressed aerobic glycolysis within these cells, indicating a direct metabolic intervention. The most impactful finding from the study was observed in vivo:
c-Apelin-12 treatment significantly decreased atherosclerotic plaque formation in an animal model. This was accompanied by a reduced expression of proliferation-associated markers and key glycolytic enzymes, confirming the peptide's mechanism of action in a living system. These findings collectively suggest that c-Apelin-12 mitigates Apelin-13-induced VSMC proliferation and atherosclerotic progression by alleviating the metabolic shift towards aerobic glycolysis.
Key Findings
- 1,12-cyclic-Apelin-12 (c-Apelin-12) was developed by cyclizing Apelin-12's N- and C-termini.
- c-Apelin-12 effectively attenuated Apelin-13-induced vascular smooth muscle cell (VSMC) proliferation in vitro.
- The peptide reduced mitochondrial injury and suppressed aerobic glycolysis in VSMCs.
- In vivo, c-Apelin-12 treatment significantly decreased atherosclerotic plaque formation.
- c-Apelin-12 reduced expression of proliferation-associated markers and key glycolytic enzymes in vivo.
Why It Matters
This research introduces c-Apelin-12 as a promising therapeutic candidate for atherosclerosis, offering a novel mechanism by targeting aerobic glycolysis and VSMC proliferation. For biohackers and clinicians, this opens a new avenue beyond traditional lipid-lowering or anti-inflammatory strategies, potentially addressing a core driver of plaque progression. The focus on a cyclized peptide suggests improved stability and bioavailability, which are critical for clinical translation. While still in preclinical stages, the findings highlight that modulating the Apelin system and aerobic glycolysis could be a powerful approach to prevent or reverse atherosclerosis. Future research will need to establish specific dosing, routes, and safety profiles in human trials, but the metabolic pathway targeted here is highly relevant to cardiovascular health.
apelin
c-apelin-12
atherosclerosis
vsmc
aerobic-glycolysis
preclinical-animal